Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

Phase 1b Trial to Evaluate Safety, Tolerability and Immune Responses of 2 Monovalent Chimpanzee Adenoviral Vectored Filovirus (Ebola-S and Marburg) Vaccines to Healthy Adults, Collection of Plasma/Serum for the Purposes of Assay Development

Primary Objective:

• To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.

Secondary Objectives:

• To evaluate the antibody response to Monovalent Chimpanzee Adenoviral Vectored Filovirus Ebola-S (cAd3-EBO-S) and Monovalent Chimpanzee Adenoviral Vectored Filovirus (Marburg) (cAd3 Marburg) vaccines as assessed by antigen glycoprotein (GP) specific (enzyme-linked immunosorbent assay) ELISA
• To collect sufficient post-vaccination plasma to support further development of filovirus assays

Study Overview

• Status: Completed
• Conditions: Ebola Virus Disease; Marburg Virus Disease
• Intervention / Treatment: Biological: cAd3-Marburg; Biological: cAd3-EBO-S

Detailed Description

Primary Endpoints: Safety

Assessment of product safety will include clinical observation and monitoring of clinical chemistry and hematology parameters. Safety will be closely monitored after injection and evaluated through Day 99 and one additional safety follow-up telephone call on Day 181 (± 14 Days). The following parameters will be assessed:

• Occurrence and severity of solicited local reactogenicity signs and symptoms for 7 days following the vaccination
• Occurrence and severity of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination
• Change from baseline for safety laboratory measures
• Occurrence of adverse events of all severities through 28 days after vaccination
• Occurrence of serious adverse events and new chronic medical conditions through the last safety follow up call at Day 181(± 14 days)

Secondary Endpoints :

• Antibody levels against vaccines cAd3-EBO-S and cAd3 Marburg as measured by enzyme-linked immunosorbent assay (ELISA) on Day 1, 15, 22, 29, 36, 43, 50, 57 and 64
• 20 Liters of plasma per vaccine group will be collected for the purpose of assay development

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • Oklahoma Blood Institute (OBI)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 46 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female participant must be between 18-50 (inclusive) years of age;
• Meet criteria for plasma donation*;
• Available for clinic follow-up through Day 99 and one additional follow-up call on Day 181 (±14 days);
• Agrees not to receive any vaccine from day of enrollment through Day 99;
• Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process;
• Agree to have photos taken of the vaccination site, if indicated ;
• Willing to complete repeated plasmapheresis and other protocol requirements;
• Must complete an Assessment of Understanding (AoU) by answering 9 out of 10 questions correctly at least once in 3 attempts;
• Willing to donate blood for sample storage and future unspecified assay development;
• Able to read (English) and willing to complete informed consent process;
• In good general health without clinically significant medical history, based on medical history, physical examination, vital signs and clinical laboratory results;
• Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) ≥ 17 and ≤ 35 within the 28 days prior to vaccination;
• Laboratory Criteria within 28 days prior to vaccination (normal per testing laboratory) for: complete blood count (CBC) with differential count, alanine aminotransferase (ALT), serum creatinine and total protein;
• Serology screen negative for infectious diseases (hepatitis B, hepatitis C, HIV, HTLV (Human T-cell leukemia lymphoma virus), Chagas disease, Syphilis;
• Nucleic acid test (NAT) negative for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), West Nile and Zika;
• Negative antibody and reverse transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome Covid 2 (SARS CoV-2) and free of current or prior symptoms concerning for COVID-19. Participants with a previous positive RT-PCR, at least 90 days prior to screening as reported in medical history, will not be excluded if they are antibody negative;

• Female participant specific criteria:

  • Negative pregnancy serum test at screening and, negative urine pregnancy test before vaccination unless one of the following criteria is met:
• At least 1 year post-menopausal;

• Surgically sterile;

  • Use of oral, implantable, transdermal or injectable contraceptives for 21 days prior to and agrees to use through Day 181 ;
  • Use of another reliable form of contraception must be approved by the Investigator (e.g., double barrier method, Depo-Provera, intrauterine device, Norplant, oral contraceptives, contraceptive patches);

• Male participants must agree:

  • Not to father a child or donate sperm through Day 181;
  • To use an effective means of birth control from at least 21 days prior to enrollment through Day 181 if assessed to be of reproductive potential.

Meet the criteria described in the AABB (formerly known as American Association of Blood Bank) and Uniform Donor History Questionnaire, with the exception of travel for malaria or Variant Creutzfeldt-Jakob Disease (vCJD) risk

Exclusion Criteria:

• Investigational COVID-19, Ebola or Marburg vaccine in a prior clinical trial or prior receipt of a cAd3 adenoviral vectored investigational vaccine;

  • Use of immunomodulators and systemic glucocorticoids in daily doses of glucocorticoid equivalence > 20 mg of prednisolone in the last 90 days and for periods exceeding 10 days. Non-steroidal anti-inflammatory drugs [NSAIDS] are permitted. Participants that have used less than the stated glucocorticoid dose may still be excluded at the Investigator's discretion;
  • Blood products within 112 days prior to enrollment;
  • Investigational research agents within 90 days prior to enrollment;
  • Any licensed vaccine, inclusive of "live-attenuated" vaccine (e.g., oral polio, yellow fever, measles, etc.), killed, or subunit vaccine, within 28 days prior to enrollment;
  • Any experimental vaccines within 6 months prior to enrollment;
  • Current anti-tuberculosis prophylaxis or therapy;
• Female participant specific criteria: woman who is pregnant, breast-feeding or planning to become pregnant through Day 181 (±14 days);
• Unsatisfactory vein assessment for plasmapheresis via peripheral access (more details in Section 5.2.1)

• History of any of the following clinically significant conditions:

  • Serious adverse reactions to vaccines such as anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain;
  • Allergic reaction to excipients in the study vaccine including gentamycin, neomycin or streptomycin;
  • Clinically significant autoimmune disease or immunodeficiency;
  • Asthma that is not well controlled;
  • Positive result on a rapid plasma regain (RPR) test (A blood test for Syphilis);
  • Diabetes mellitus Type I or II;
  • Thyroid disease that is not well controlled ;
  • A history of hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema;
  • Idiopathic urticaria within the last 1 year;
  • Hypertension that is not well controlled;
  • Bleeding disorder diagnosed by a doctor or use of anticoagulant medications such as, Coumadin, Eliquis, Pradaxa (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws;
  • A malignancy that is active, currently being treated, or not surgically cured (breast or prostate cancer successfully treated, with or without surgery is excluded; if diagnosed malignancy is 5 or more years prior to enrollment and cured with no ongoing treatment it will NOT be considered an exclusion);
  • Seizure in the past 3 years or treatment for seizure disorder in the past 3 years;
  • Asplenia or functional asplenia;
  • Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within five years prior to enrollment, history of a suicide plan or attempt;
  • Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a participant's ability to give informed consent.
  • Abnormal laboratory results (per testing laboratory)
  • Positive COVID-19 symptom screen, SARS-CoV-2 RT-PCR, or SARS CoV-2 antibody test

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: cAd3-Marburg at 1 x 10^11 Particle Units (PU); A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10^11 Particle Units (PU) vaccine.	Biological: cAd3-Marburg; A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 1 (N = 16) will receive a single injection of cAd3-Marburg at 1 x 10^11 Particle Units (PU) vaccine.
Active Comparator: cAd3-EBO-S at 1 x 10^11 PU vaccine; A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10^11 Particle Units (PU) vaccine.	Biological: cAd3-EBO-S; A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10^11 Particle Units (PU) vaccine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of Ebola and Marburg vaccines assessed by clinical observation.	Safety of Ebola and Marburg vaccines, as seen in local reactogenicity signs and symptoms with diary questionnaire card.	7 Days
Safety of Ebola and Marburg vaccines assessed by clinical observation.	Safety of Ebola and Marburg vaccines, as seen in systemic reactogenicity signs and symptoms with diary questionnaire card.	7 Days
Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Complete Blood Count (CBC).	Safety of Ebola and Marburg vaccines assessed by change in levels of Complete Blood Count (CBC) w/differential count as laboratory measures of safety from baseline.	6 months
Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Creatinine.	Safety of Ebola and Marburg vaccines assessed by change in levels of Creatinine as laboratory measures of safety from baseline.	6 months
Safety of Ebola and Marburg vaccines assessed by change from baseline in levels of Alanine Transaminase (ALT).	Safety of Ebola and Marburg vaccines assessed by change in levels of Alanine Transaminase (ALT) as laboratory measures of safety from baseline.	6 months
Safety of Ebola and Marburg vaccines assessed by adverse experiences.	Safety of Ebola and Marburg vaccines assessed by adverse events of all severities (Mild, moderate, and severe)	28 days
Safety of Ebola and Marburg vaccines assessed by serious adverse experiences.	Safety of Ebola and Marburg vaccines assessed by serious adverse events of all severities (Mild, moderate, and severe)	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of antibody response to cAd3-EBO-S and cAd3 Marburg vaccines	Immunogenicity of the Ebola and Marburg vaccines as measured by antigen GP-specific ELISA	Measured at Day 1, 15, 22, 29, 36, 43, 50, 57, and 64
Collection of sufficient post-vaccination plasma to support further development of filovirus assays.	20 L of plasma per vaccine group (N=2) will be collected for the purpose of assay development. 800 mL of plasma will be collected at Day 29. Thereafter, plasma collections will be up to approximately 600 mL. Participants may donate up to 6 total times and all collections will be done within the limits of the FDA approved instructions for use for the Fenwal Alyx collection device.	May be collected at Day 29, 36, 43, 50, 57 and/or 64

Collaborators and Investigators

• Sponsor: Albert B. Sabin Vaccine Institute
• Collaborators: ICON plc; Oklahoma Blood Institute
• Investigators: Study Chair: Roxana Rustomjee, MBChB, The Albert B. Sabin Vaccine Institute; Principal Investigator: Michael Stevenson, MD, Oklahoma Blood Institute; Study Director: David Hoover, MD, ICON plc; Principal Investigator: Tuan Le, MD, Oklahoma Blood Institute

Publications and helpful links

General Publications

• Sanchez A, Kiley MP, Klenk HD, Feldmann H. Sequence analysis of the Marburg virus nucleoprotein gene: comparison to Ebola virus and other non-segmented negative-strand RNA viruses. J Gen Virol. 1992 Feb;73 ( Pt 2):347-57. doi: 10.1099/0022-1317-73-2-347.
• Sanchez A, Kiley MP, Holloway BP, Auperin DD. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 1993 Sep;29(3):215-40. doi: 10.1016/0168-1702(93)90063-s.
• Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med. 2004 Dec;10(12 Suppl):S110-21. doi: 10.1038/nm1142.
• Hensley LE, Jones SM, Feldmann H, Jahrling PB, Geisbert TW. Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr Mol Med. 2005 Dec;5(8):761-72. doi: 10.2174/156652405774962344.
• Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham BS; VRC 207 Study Team. Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med. 2017 Mar 9;376(10):928-938. doi: 10.1056/NEJMoa1410863. Epub 2014 Nov 26.

Study record dates

Study Major Dates

• Study Start (Actual): January 6, 2021
• Primary Completion (Actual): December 14, 2021
• Study Completion (Actual): December 14, 2021

Study Registration Dates

• First Submitted: December 10, 2020
• First Submitted That Met QC Criteria: January 20, 2021
• First Posted (Actual): January 26, 2021

Study Record Updates

• Last Update Posted (Actual): August 3, 2022
• Last Update Submitted That Met QC Criteria: August 2, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: Human immunodeficiency virus; Acquired Immunodeficiency Syndrome; Activities of Daily Living; Hepatitis C Virus; Intravenous; Hereditary Angioedema; Severe Acute Respiratory Syndrome Coronavirus 2; Complete blood count; Body mass index; Ebola Hemorrhagic Fever; Hepatitis B Virus; Alanine aminotransferase; Coronavirus Disease; Enzyme-Linked Immunosorbent Assay; Immunoglobulin G; Immunoglobulin M; Adverse Event; Identification; Glycoprotein; Center for Disease Control and Prevention; Ebola Virus Disease; Modified Vaccinia Ankara; Creatine phosphokinase; Clinical Research Associate; Contract Research Organization; Division of AIDS; Disseminated Intravascular Coagulation; Diagnostic Lab of Oklahoma; Deoxyribonucleic Acid; Species Zaire Ebolavirus; Electronic Case Report Form; Ethylenediaminetetraacetic Acid; Food and Drug Administration; Degrees Fahrenheit; Good Clinical Practices; Good Laboratory Practices; Grams; Government and Public Health Solutions; GlaxoSmithKline; Hemagglutinin; Human T-cell Leukemia Lymphoma Virus; Investigator's Brochure; International Council for Harmonisation; International Committee on the Taxonomy of Viruses; Intramuscular(ly); Investigational New Drug; Investigational product; Marburg Virus; Marburg Virus Disease; Marburg hemorrhagic fever; Milliliter; Millimeters of Mercury; Nucleic Acid Test; Non-Disclosure Agreement; Non-Human Primate; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Nucleoprotein; Nonsteroidal Anti-Inflammatory Drug; Oklahoma Blood Institute; Office for Human Research Protection; Plasmapheresis Assessment Review Team; Plaque Forming Unit; Physical Exam; Principal Investigator; Post Injection Reactogenicity; Project Manager; Prothrombin Time; Partial Thromboplastin Time; Particle Units; Ravn Virus; Recombinant Human Adenovirus Serotype 5; Species Reston ebolavirus; Ribonucleic Acid; Rapid Plasma Regain; Reverse Transcription Polymerase Chain Reaction; Serious Adverse Event; Statistical Analysis System; Schedule of Events; Standard Operating Procedure; Serum Separator Tube; Species Sudan Ebolavirus; Suspected, Unexpected and Serious Adverse Reaction; Species Taï Forest Ebolavirus; Technical Resources International, Inc; Universal Donor History Questionnaire; Upper Limit of Normal; Viral Particles; Vaccine Research Center; Vesicular Stomatitis Virus; Variant Creutzfeldt-Jakob Disease; White blood cell; World Health Organization; Western Institutional Review Board; Wild type; Zaire Ebola virus; Acquired Angioedema; Program, Inc.; Human adenovirus Serotype 5; Assessment of Understanding; Aspartate Aminotransferase; Biomedical Advanced Research and Development Authority; Species Bundibugyo ebolavirus; Blood Establishment Computer System; Blood Urea Nitrogen; Recombinant Chimpanzee Adenovirus Serotype 3; Recombinant Chimpanzee Adenovirus; Recombinant Chimpanzee Adenovirus Serotype 63; Code of Federal Regulations; Confidence Interval; Centimeters; Type 3-Vectored Ebola virus Vaccine; Type 3-Vectored Ebola Sudan Vaccine; Type 3-Vectored Marburg Vaccine
• Additional Relevant MeSH Terms: RNA Virus Infections; Infections; Mononegavirales Infections; Hemorrhagic Fevers, Viral; Filoviridae Infections; Virus Diseases; Hemorrhagic Fever, Ebola; Marburg Virus Disease
• Other Study ID Numbers: Sabin 001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No